-
Product Insights
Net Present Value Model: Brii Biosciences Ltd’s BRII-179 + BRII-835
Empower your strategies with our Net Present Value Model: Brii Biosciences Ltd's BRII-179 + BRII-835 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Myocardial Infarction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Myocardial Infarction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase Biosimilar in Myocardial Infarction Drug Details: Tenecteplase biosimilar (GNR-060) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KUR-101 in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.KUR-101 in Pain Drug Details:KUR-101 (deuterated mitragynine) is under investigation for the treatment of pain and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KUR-101 in Opium (Opioid) Addiction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.KUR-101 in Opium (Opioid) Addiction Drug Details:KUR-101 (deuterated mitragynine) is under investigation for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RL-007 in Diabetic Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RL-007 in Diabetic Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RL-007 in Diabetic Neuropathic Pain Drug Details:RL-007 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RL-007 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RL-007 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RL-007 in Cognitive Impairment Associated With Schizophrenia (CIAS)Drug Details:RL-007...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Blinatumomab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Blinatumomab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Blinatumomab in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Blinatumomab (Blincyto)...
-
Product Insights
Egyptian National Railways – Dual line to Atay al-Baroud – Egypt – Beheira
Equip yourself with the essential tools needed to make informed and profitable decisions with our Egyptian National Railways - Dual line to Atay al-Baroud - Egypt - Beheira report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
Net Present Value Model: RL-007
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RL-007 Drug Details RL-007 is under...